The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
By Wen Zhang, Yan Zhao, Fengchun Zhang, Qian Wang, Taisheng Li, Zheng-yin Liu, Jinglan Wang, Yan Qin, Xuan Zhang, Xiaowei Yan and 2 more. Clinical Immunology, 2020
1,221 citations recorded by the source corpus.
The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world. Reports from China showed that about 20% of patients developed severe disease, resulting in a fatality of 4%. In the past two months, we clinical immunologists participated in multi-rounds of MDT (multidiscipline team) discussion on the anti-inflammation management of critical COVID-19 patients, with our colleagues dispatched from Chinese leading PUMC Hospital to Wuhan to admit and treat the most severe patients. Here, from the perspective of clinical immunologists, we will discuss the clinical and immunological characteristics of severe patients, and summarize the current evidence and share our experience in anti-inflammation treatment, including glucocorticoids, IL-6 antagonist, JAK inhibitors and choloroquine/hydrocholoroquine, of patients with severe COVID-19 that may have an impaired immune system.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/9421224576edc107e7a38172667687a8a97b8300
Citations in the corpus
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach (2020, neutral): “● Potential therapy for severe COVID-19 patients ● The convalescent plasma is retrieved from the fully recovered patients of viral disease and is transfused in the infected person as a treatment strategy ● During the time of the COVID-19 pandemic, the successful application of this therapy is effect”
- SARS-CoV-2 infection: The role of cytokines in COVID-19 disease (2020, neutral): “[58] Literature review To study the use of anti-inflammatory drugs in the”